Biologics License Application for omburtamab for the treatment of paediatric patients with CNS/leptomeningeal metastasis from neuroblastoma submitted to the US FDA

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule widely expressed in tumour cells of several cancer types. The submission is based on data from two Phase 2 studies, due for presentation later this year.


Biospace Inc.